InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,222.68
(
0.00%
)
US TECH 100
17,731.59
(
0.28%
)
Dow Jones
39,512.84
(
0.00%
)
Brent Oil
83.15
(
0.92%
)
Bitcoin
62,737.99
(
2.10%
)
Post# of 19459
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

poods

Send PM Follow Ignore
Followers 1
Posts 114
Boards Moderated 0
Alias Born 12/26/2017

poods

Re: Myplace post# 5501

Sunday, 01/07/2018 12:46:23 PM

Sunday, January 07, 2018 12:46:23 PM

Post# of 19459
The very impressive Zika and hemorrhagic fever results in animals are new talking points. Also, because major issues have arisen for Sanofi's Dengvaxia, the opportunities in the flavivirus area, given that GOVX anticipated and designed its Zika virus vaccine to avoid the problem (antibody dependent enhancement), may be opening up. This may interest a suitor.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent GOVX News
More GOVX News
InvestorsHub NewsWire

Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM

VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM

Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM

Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM

Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM

Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM

Start posting your company's news
Only $200 per official company press release!